Showing 3351-3360 of 5646 results for "".
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- SightLife Announces 100,000 Corneal Transplants in India Since Program Inception in 2009https://modernod.com/news/sightlife-announces-100000-corneal-transplants-in-india-since-program-inception-in-2009/2476639/SightLife announced that, together with its partners in India, 100,000 individuals suffering from corneal blindness have had their sight restored through a corneal transplant in the last 10 years since operations began in India. SightLife is a nonprofit global health organization dedicated to eli
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- Leiters Now Integrated into Besse Medical’s Inventory Management Systemshttps://modernod.com/news/leiters-now-integrated-into-besse-medicals-inventory-management-systems/2476547/Leiters and Besse Medical announced that they have entered into a national agreement to provide ophthalmic medications that are compatible with Besse Medical’s inventory management systems, CubixxMD and PODIS Plus. This new agreement enables Leiters’ full suite of ophthalmic medicatio
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- IStent Inject Device Lowers IOP After Cataract Surgery in Glaucoma Patientshttps://modernod.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/In patients with mild to moderate glaucoma and cataract, the second-generation iStent inject system, with two redesigned stents, reduces IOP more than cataract surgery alone, according to results of a new pivotal trial, as reported by Reut
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o